<p>Biocon has received approval from the Japanese health authority to sell its biosimilar product ‘Insulin Glargine’ from the first quarter of the next fiscal.<br /><br /></p>.<p>In a teleconference on Monday, Biocon CEO and JMD Arun Chandavarkar said it is a great achievement for the company.<br /><br />“We have succeeded in getting access to highly regulated market like Japan, which is the second largest market for insulin after North America. This will help us expand our reach in other regulated markets like North America and Europe by FY 2017,” he said.<br /><br />Biocon got the approval from the Ministry of Health, Labour and Welfare (MHLW) of Japan to sell Glargine through its commercial partner Fujifilm Pharma.<br /><br />Chandavarkar said the insulin market in Japan is around $140 million. <br /><br />Biocon’s product is a ready-to-use prefilled disposable pen with 3 ml of 100IU Insulin Glargine.</p>
<p>Biocon has received approval from the Japanese health authority to sell its biosimilar product ‘Insulin Glargine’ from the first quarter of the next fiscal.<br /><br /></p>.<p>In a teleconference on Monday, Biocon CEO and JMD Arun Chandavarkar said it is a great achievement for the company.<br /><br />“We have succeeded in getting access to highly regulated market like Japan, which is the second largest market for insulin after North America. This will help us expand our reach in other regulated markets like North America and Europe by FY 2017,” he said.<br /><br />Biocon got the approval from the Ministry of Health, Labour and Welfare (MHLW) of Japan to sell Glargine through its commercial partner Fujifilm Pharma.<br /><br />Chandavarkar said the insulin market in Japan is around $140 million. <br /><br />Biocon’s product is a ready-to-use prefilled disposable pen with 3 ml of 100IU Insulin Glargine.</p>
